Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 17/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.48 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18762028 | 0.80 | MKNK1 (0.63) | MKNK1LIMK1 | |
| SCHEMBL940518 | 0.76 | MKNK1 (0.48) | MKNK1LIMK1 | |
| SCHEMBL17296473 | 0.76 | MKNK1 (0.48) | MKNK1LIMK1 | |
| SCHEMBL17307632 | 0.75 | EGFR (0.48) | MKNK1P2RX3 | |
| SCHEMBL17296440 | 0.75 | P2RX3 (0.49) | MKNK1P2RX3LIMK1 | |
| SCHEMBL17307739 | 0.73 | P2RX3 (0.47) | MKNK1P2RX3LIMK1 | |
| SCHEMBL967213 | 0.73 | RXFP1 (0.66) | MKNK1 | |
| SCHEMBL12908869 | 0.73 | MKNK1 (0.48) | MKNK1LIMK1 | |
| SCHEMBL17307692 | 0.72 | P2RX3 (0.48) | MKNK1P2RX3LIMK1 | |
| SCHEMBL937868 | 0.72 | MKNK1 (0.70) | MKNK1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107229-A1 | SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-20 | — | — | US | claimed |
| US-20170107229-A1 | SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-20 | — | — | US | disclosed |
| US-20170107229-A1 | SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-20 | — | — | US | disclosed |
| US-20170107229-A1 | SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-20 | — | — | US | disclosed |
| WO-2015181063-A1 | SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107229-A1 | SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES | TYMP, DPYD, TYMS | MKNK1 2433/4885P2RX3 1911/4885LIMK1 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.